Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I/II Trial of Abraxane® (ABI-007) and Alimta® (Pemetrexed) in Advanced Solid Tumors With Emphasis on Non-Small Cell Lung Cancer (NSCLC) and Breast Cancer

NCT00470548 is registered in ClinicalTrials.gov with University of California, Davis as lead sponsor.

NCT NCT00470548
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00470548 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I/II Trial of Abraxane® (ABI-007) and Alimta® (Pemetrexed) in Advanced Solid Tumors With Emphasis on Non-Small Cell Lung Cancer (NSCLC) and Breast Cancer
Lead sponsor
University of California, Davis
Phase
Phase 1/2
Overall status
Terminated
Start date
April 30, 2007
Completion date
October 31, 2014
Enrollment
49 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, lung cancer, unspecified adult solid tumor, protocol specific